Pharmacokinetic/pharmacodynamic model models

The focus of this book is primarily on the development of pharmacokinetic and pharmacokinetic-pharmacodynamic models. Models that are reported in the literature are not picked out of thin air. Useful models take time and effort and what is rarely shown is the process that went into developing that model. The purpose of this chapter is to discuss model development, to explain the process, and to introduce concepts that will be used throughout this book. Those criteria used to select a model extend to whether the model is a linear... [Pg.1]

Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G (2002) Ribavirin dosing in chronic hepatitis C application of population pharmacokinetic-pharmacodynamic models, Clin Pharmacol Ther 72 349-361... [Pg.235]

Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000 40 67-95. [Pg.525]

Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997 35 469-74. [Pg.525]

Schaddelee MP, Collins SD, DeJongh J, de Boer AG, Ijzerman AP, Danhof M. Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and antinociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. Eur J Pharmacol 2005 May 9 514(2-3) 131-40. [Pg.553]

Duffal SB, Kimko HC (eds). Simulation for designing clinical trials a pharmacokinetic-pharmacodynamic modeling perspective (Drugs and the pharmaceutical sciences, Vol 127). New York Marcel Dekker, 2003... [Pg.553]

Rosario MC, Jacqmin P, Dorr P, van der Ryst E, Hitchcock C. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther 2005 78(5) 508-519. [Pg.192]

Simulation for Designing Clinical Trials A Pharmacokinetic-Pharmacodynamic Modeling Perspective, edited by Hui C. Kimko and Stephen B. Duffull... [Pg.10]

Gobburu, J. V., Marroum, P. J., Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory dedsion-... [Pg.439]

Part 2 Pharmacokinetic/Pharmacodynamic Modeling in New Drug Development... [Pg.345]

C(t) modeled according to two-compartment model with zero-order and first-order absorption Pharmacokinetic/pharmacodynamic relationship modeled using Hill model with first-order absorption. Modeled parameters matched experimental parameters when bicompartmental model with zero-order input was used. Linear PKs, anticlockwise hysteresis loop established for all doses studied. Apomorphine and growth hormone concentration predicted with good accuracy... [Pg.369]

Pharmacokinetic/pharmacodynamic model using nonlinear, mixed-effects model in two compartment, best described time course of concentration strong correlation with creatinine clearance predicted concentration at the efi ect site and in reduction of heart rate during atrial fibrillation using population kinetic approach... [Pg.369]

Pharmacokinetic/pharmacodynamic modeling indicates that the AUC/MIC ratio is predictive of outcome for this antibacterial suggesting that telithromycin is suitable for short-duration therapy and a once-daily dosing regimen even against / -lactam and macrolide-resistant pathogens... [Pg.369]

Landoni, M.F. and Lees, P., Pharmacokinetic/pharmacodynamic modeling of non-steroidal anti-inflammatory drugs,/. Vet. Pharmacol. Ther., 20,118-120,1997. [Pg.374]

Varlet-Marie, E., Gaudard, A., Audran, M., Gomeni, R., and Bressolle, F., Pharmacokinetic-pharmacodynamic modeling of recombinant human erythropoietin in athletes, Int. J. Sports Med., 24,2S2-2S7,2003. [Pg.374]

Lin, S. and Ghien, Y.W., Pharmacokinetic-pharmacodynamic modeling of insulin comparison of indirect pharmacodjmamic response with effect-compartment link models, J. Pharm. Pharmacol, 54, 791-800, 2002. [Pg.374]

Csajka, C., Buclin, T., Fattinger, K., Brunner, H.R., and Biollaz, Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers, Clin. Pharmacokinet., 41, 137-152, 2002. [Pg.376]

Miyazaki, M., Mukai, H., Iwanaga, K., Morimoto, K., and Kakemi, M., Pharmacokinetic-pharmacodynamic modeling of human insulin validity of pharmacological availability as a substitute for extent of bioavailability, /. Pharni. Pharmacol., 53, 1235-1246, 2001. [Pg.376]

Dalla Gosta, T., Nolting, A., Rand, K., and Derendorf, H., Pharmacokinetic-pharmacodynamic modeling of the in vitro antiinfective effect of piperacillin-tazobactam combinations, Int.. Clin. Pharmacol. Ther., 35, 426-433,1997. [Pg.376]

Koopmans, R., Oosterhuis, B., Karemaker, J.M., Werner, J., and van Boxtel, C.J., Pharmacokinetic-pharmacodynamic modeling of oxprenolol in man using continuous non-invasive blood pressure monitoring, Eur.. Clin. Pharmacol., 34, 395-400,1988. [Pg.376]

Rnally, pharmacokinetic and pharmacokinetic/pharmacodynamic modelling can be used for the purpose of prediction of the concentration-time profile of the drug and drug-carrier conjugate after repeated administration from single dose data, as well as for the prediction of the dose needed to maintain the concentration at the target site within a therapeutic window. [Pg.334]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...